Pharsight

Drugs facing NCE-1 in 2024

1. Avycaz patents expiration

AVYCAZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178554 ALLERGAN Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents
Jul, 2021

(2 years ago)

US7112592 ALLERGAN Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Jan, 2026

(1 year, 6 months from now)

US8471025 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Aug, 2031

(7 years from now)

US8969566 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(8 years from now)

US9284314 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(8 years from now)

US9695122 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612087 ALLERGAN Heterocyclic compounds as inhibitors of beta-lactamases
Nov, 2026

(2 years from now)

US8835455 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 25, 2020
New Patient Population(NPP) Dec 20, 2025
Generating Antibiotic Incentives Now(GAIN) Feb 25, 2025
New Indication(I-738) Jun 22, 2019

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 26 February, 2024

Market Authorisation Date: 25 February, 2015

Treatment: A method of treating a bacterial infection in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) patients comprising administering an effective amount of a...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

AVYCAZ family patents

Family Patents

2. Ayvakit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9200002 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(10 years from now)

US9944651 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(10 years from now)

US9994575 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(10 years from now)

US11827642 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-863) Jun 16, 2024
New Chemical Entity Exclusivity(NCE) Jan 09, 2025
New Indication(I-864) Jun 16, 2024
Orphan Drug Exclusivity(ODE-356) Jun 16, 2028
Orphan Drug Exclusivity(ODE-434) May 22, 2030
Orphan Drug Exclusivity(ODE-366) Jan 09, 2027
New Indication(I-912) May 22, 2026

Drugs and Companies using AVAPRITINIB ingredient

NCE-1 date: 10 January, 2024

Market Authorisation Date: 16 June, 2021

Treatment: Treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leu...

Dosage: TABLET;ORAL

More Information on Dosage

AYVAKIT family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Barhemsys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9545426 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(6 years from now)

US9889118 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(6 years from now)

US10525033 ACACIA Use of amisulpride as an anti-emetic
Mar, 2031

(6 years from now)

US9084765 ACACIA Use of amisulpride as an anti-emetic
Feb, 2034

(9 years from now)

US11357753 ACACIA Rescue treatment of post operative nausea and vomiting
Feb, 2038

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: 27 February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Prevention of post-operative nausea and vomiting; Prevention and treatment of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

BARHEMSYS family patents

Family Patents

4. Brilinta patents expiration

BRILINTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6251910 ASTRAZENECA 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
Jul, 2018

(5 years ago)

US7250419 ASTRAZENECA Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
Dec, 2019

(4 years ago)

US6525060 ASTRAZENECA Triazolo(4,5-d)pyrimidine compounds
Dec, 2019

(4 years ago)

US7265124 ASTRAZENECA Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
Jul, 2021

(2 years ago)

USRE46276 ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Oct, 2024

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6251910 ASTRAZENECA 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
Jul, 2018

(5 years ago)

US7250419 ASTRAZENECA Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
Dec, 2019

(4 years ago)

US6525060 ASTRAZENECA Triazolo(4,5-d)pyrimidine compounds
Dec, 2019

(4 years ago)

US7265124 ASTRAZENECA Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
Jul, 2021

(2 years ago)

USRE46276

(Pediatric)

ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Apr, 2025

(10 months from now)

US8425934 ASTRAZENECA Pharmaceutical compositions
Apr, 2030

(5 years from now)

US8425934

(Pediatric)

ASTRAZENECA Pharmaceutical compositions
Oct, 2030

(6 years from now)

US10300065 ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jan, 2036

(11 years from now)

US10300065

(Pediatric)

ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-848) Nov 05, 2023
M(M-283) May 09, 2025
Pediatric Exclusivity(PED) Nov 09, 2025
New Indication(I-851) May 28, 2023
New Strength(NS) Sep 03, 2018
New Indication(I-714) Sep 03, 2018
New Chemical Entity Exclusivity(NCE) Jul 20, 2016

Drugs and Companies using TICAGRELOR ingredient

NCE-1 date: 09 November, 2024

Market Authorisation Date: 03 September, 2015

Treatment: Reduction of the rate of thrombotic events in patients with acute coronary syndrome; Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspir...

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage

BRILINTA family patents

Family Patents

5. Byfavo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10961250 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(3 years from now)

US9777007 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(3 years from now)

US10472365 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(3 years from now)

US9914738 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(3 years from now)

US10722522 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(7 years from now)

US9827251 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(7 years from now)

US9737547 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(7 years from now)

US10052334 ACACIA Dosing regimen for sedation with CNS 7056 (remimazolam)
Nov, 2031

(7 years from now)

US10195210 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(7 years from now)

US10342800 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Nov, 2031

(7 years from now)

US9561236 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam)
Apr, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 06, 2025

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

NCE-1 date: 06 October, 2024

Market Authorisation Date: 06 October, 2020

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

BYFAVO family patents

Family Patents

6. Dayvigo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8268848 EISAI INC Cyclopropane compound
Sep, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11026944 EISAI INC Compositions and methods for treating insomnia
Oct, 2035

(11 years from now)

US10702529 EISAI INC Compositions and methods for treating insomnia
Oct, 2035

(11 years from now)

US10188652 EISAI INC Compositions and methods for treating insomnia
Oct, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 07, 2025
M(M-293) Apr 20, 2026

Drugs and Companies using LEMBOREXANT ingredient

NCE-1 date: 07 April, 2024

Market Authorisation Date: 07 April, 2020

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

More Information on Dosage

DAYVIGO family patents

Family Patents

7. Detectnet patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10159759 RADIOMEDIX Pet tracer for imaging of neuroendocrine tumors
Aug, 2032

(8 years from now)

US11160888 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors
Aug, 2032

(8 years from now)

US10383961 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors
Aug, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 03, 2025
Orphan Drug Exclusivity(ODE-317) Sep 03, 2027

Drugs and Companies using COPPER CU-64 DOTATATE ingredient

NCE-1 date: 03 September, 2024

Market Authorisation Date: 03 September, 2020

Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

DETECTNET family patents

Family Patents

8. Dojolvi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186344 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Jul, 2025

(1 year, 22 days from now)

US8697748 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Apr, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-311) Jun 30, 2027
New Chemical Entity Exclusivity(NCE) Jun 30, 2025

Drugs and Companies using TRIHEPTANOIN ingredient

NCE-1 date: 30 June, 2024

Market Authorisation Date: 30 June, 2020

Treatment: NA

Dosage: LIQUID;ORAL

More Information on Dosage

DOJOLVI family patents

Family Patents

9. Evrysdi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9586955 GENENTECH INC Compounds for treating spinal muscular atrophy
Feb, 2033

(8 years from now)

US9969754 GENENTECH INC Compounds for treating spinal muscular atrophy
May, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11827646 GENENTECH INC Compounds for treating spinal muscular atrophy
Jan, 2036

(11 years from now)

US11534444 GENENTECH INC Treatment of SMA
Oct, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-334) Aug 07, 2027
New Chemical Entity Exclusivity(NCE) Aug 07, 2025
Orphan Drug Exclusivity(ODE-400) May 27, 2029
New Patient Population(NPP) May 27, 2025
M(M-270) Oct 03, 2026

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: 07 August, 2024

Market Authorisation Date: 07 August, 2020

Treatment: Treatment of spinal muscular atrophy

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

EVRYSDI family patents

Family Patents

10. Gavreto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10030005 BLUEPRINT MEDICINES Inhibitors of RET
Nov, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273160 BLUEPRINT MEDICINES RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(14 years from now)

US11872192 BLUEPRINT MEDICINES RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 04, 2025
Orphan Drug Exclusivity(ODE-341) Dec 01, 2027
Orphan Drug Exclusivity(ODE-340) Dec 01, 2027
Orphan Drug Exclusivity(ODE-318) Sep 04, 2027

Drugs and Companies using PRALSETINIB ingredient

NCE-1 date: 04 September, 2024

Market Authorisation Date: 04 September, 2020

Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatri...

Dosage: CAPSULE;ORAL

More Information on Dosage

GAVRETO family patents

Family Patents

11. Gemtesa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8653260 UROVANT Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
Apr, 2029

(4 years from now)

US8247415 UROVANT Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists
Dec, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 23, 2025

Drugs and Companies using VIBEGRON ingredient

NCE-1 date: 23 December, 2024

Market Authorisation Date: 23 December, 2020

Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Dosage: TABLET;ORAL

More Information on Dosage

GEMTESA family patents

Family Patents

12. Gilotrif patents expiration

GILOTRIF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6251912 BOEHRINGER INGELHEIM Substituted quinazoline derivatives
Jul, 2018

(5 years ago)

USRE43431 BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them
Jan, 2026

(1 year, 7 months from now)

US8426586 BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Oct, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43431

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them
Jul, 2026

(2 years from now)

US9539258 BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases
Nov, 2026

(2 years from now)

US9539258

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases
May, 2027

(2 years from now)

US8545884 BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992
Dec, 2029

(5 years from now)

US8426586

(Pediatric)

BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Apr, 2030

(5 years from now)

US8545884

(Pediatric)

BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992
Jun, 2030

(6 years from now)

US10004743 BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Jul, 2030

(6 years from now)

US10004743

(Pediatric)

BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Jan, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-230) Jan 12, 2025
M(M-276) Apr 07, 2025
Pediatric Exclusivity(PED) Oct 07, 2025
Orphan Drug Exclusivity(ODE) Apr 15, 2023
New Chemical Entity Exclusivity(NCE) Jul 12, 2018
New Indication(I-730) Apr 15, 2019
Orphan Drug Exclusivity(ODE-115) Apr 15, 2023
New Indication(I-763) Jan 12, 2021
Orphan Drug Exclusivity(ODE-50) Jul 12, 2020

Drugs and Companies using AFATINIB DIMALEATE ingredient

NCE-1 date: 07 October, 2024

Market Authorisation Date: 12 July, 2013

Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy; Treatment of cancer

Dosage: TABLET;ORAL

How can I launch a generic of GILOTRIF before it's drug patent expiration?
More Information on Dosage

GILOTRIF family patents

Family Patents

13. Imcivree patents expiration

IMCIVREE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9458195 RHYTHM Melanocortin receptor ligands
Oct, 2027

(3 years from now)

US8039435 RHYTHM Melanocortin receptor ligands
Oct, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129869 RHYTHM Pharmaceutical compositions
Jul, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-336) Nov 25, 2027
New Chemical Entity Exclusivity(NCE) Nov 25, 2025
Orphan Drug Exclusivity(ODE-402) Jun 16, 2029
New Indication(I-892) Jun 16, 2025

Drugs and Companies using SETMELANOTIDE ACETATE ingredient

NCE-1 date: 25 November, 2024

Market Authorisation Date: 25 November, 2020

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

IMCIVREE family patents

Family Patents

14. Inqovi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9567363 OTSUKA Certain compounds, compositions and methods
Oct, 2028

(4 years from now)

US8268800 OTSUKA Certain compounds, compositions and methods
Aug, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618075 OTSUKA Certain compounds, compositions and methods
Oct, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 07, 2025
Orphan Drug Exclusivity(ODE-316) Jul 07, 2027

Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient

NCE-1 date: 07 July, 2024

Market Authorisation Date: 07 July, 2020

Treatment: Method for inhibiting degradation of a cda substrate by administering cedazuridine

Dosage: TABLET;ORAL

More Information on Dosage

INQOVI family patents

Family Patents

15. Isturisa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8835646 RECORDATI RARE Organic compounds
Aug, 2026

(2 years from now)

US8314097 RECORDATI RARE Organic compounds
Mar, 2029

(4 years from now)

US9434754 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(6 years from now)

US10143680 RECORDATI RARE Pharmaceutical dosage forms
Jul, 2035

(11 years from now)

US10709691 RECORDATI RARE Pharmaceutical dosage forms
Oct, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 06, 2025
Orphan Drug Exclusivity(ODE-286) Mar 06, 2027

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

NCE-1 date: 06 March, 2024

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease

Dosage: TABLET;ORAL

More Information on Dosage

ISTURISA family patents

Family Patents

16. Klisyri patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8236799 ALMIRALL Biaryl compositions and methods for modulating a kinase cascade
Dec, 2025

(1 year, 6 months from now)

US8980890 ALMIRALL Compositions and methods of treating cell proliferation disorders
Dec, 2025

(1 year, 6 months from now)

US7300931 ALMIRALL Compositions for treating cell proliferation disorders
Feb, 2026

(1 year, 7 months from now)

US7851470 ALMIRALL Composition and methods for modulating a kinase cascade
Feb, 2029

(4 years from now)

US10669236 ALMIRALL Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
Sep, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10323001 ALMIRALL Compositions for modulating a kinase cascade and methods of use thereof
Dec, 2027

(3 years from now)

US11497750 ALMIRALL Methods of treating and/or preventing actinic keratosis
Mar, 2038

(13 years from now)

US10617693 ALMIRALL Methods of treating and/or preventing actinic keratosis
Mar, 2038

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2025

Drugs and Companies using TIRBANIBULIN ingredient

NCE-1 date: 14 December, 2024

Market Authorisation Date: 14 December, 2020

Treatment: Topical treatment of actinic keratosis of the face or scalp

Dosage: OINTMENT;TOPICAL

More Information on Dosage

KLISYRI family patents

Family Patents

17. Koselugo patents expiration

KOSELUGO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7425637 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2025

(9 months from now)

US8178693 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2025

(9 months from now)

US9156795 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(2 years from now)

US9562017 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11813246 ASTRAZENECA Pharmaceutical composition
Mar, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 10, 2025
Orphan Drug Exclusivity(ODE-288) Apr 10, 2027

Drugs and Companies using SELUMETINIB SULFATE ingredient

NCE-1 date: 10 April, 2024

Market Authorisation Date: 10 April, 2020

Treatment: Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)

Dosage: CAPSULE;ORAL

More Information on Dosage

KOSELUGO family patents

Family Patents

18. Lutathera patents expiration

LUTATHERA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596276 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(14 years from now)

US10596278 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(14 years from now)

US11904027 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-166) Jan 26, 2025
Pediatric Exclusivity(PED) Jul 26, 2025
New Chemical Entity Exclusivity(NCE) Jan 26, 2023

Drugs and Companies using LUTETIUM LU 177 DOTATATE ingredient

NCE-1 date: 26 July, 2024

Market Authorisation Date: 26 January, 2018

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

LUTATHERA family patents

Family Patents

19. Mekinist patents expiration

MEKINIST's oppositions filed in EPO
Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7378423 NOVARTIS Pyrimidine compound and medical use thereof
May, 2027

(2 years from now)

US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(1 year, 1 day from now)

US8835443

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Dec, 2025

(1 year, 6 months from now)

US7378423

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Nov, 2027

(3 years from now)

US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Oct, 2030

(6 years from now)

US8952018

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Apr, 2031

(6 years from now)

US8703781

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Apr, 2031

(6 years from now)

US9155706 NOVARTIS Pharmaceutical composition
Jan, 2032

(7 years from now)

US9399021 NOVARTIS Pharmaceutical composition
Jan, 2032

(7 years from now)

US8580304 NOVARTIS Pharmaceutical composition
Jan, 2032

(7 years from now)

US9271941 NOVARTIS Pharmaceutical composition
Jan, 2032

(7 years from now)

US9271941

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(8 years from now)

US9399021

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(8 years from now)

US8580304

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(8 years from now)

US9155706

(Pediatric)

NOVARTIS Pharmaceutical composition
Jul, 2032

(8 years from now)

US10869869 NOVARTIS Method of adjuvant cancer treatment
Aug, 2033

(9 years from now)

US10869869

(Pediatric)

NOVARTIS Method of adjuvant cancer treatment
Mar, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-182) Apr 30, 2025
Orphan Drug Exclusivity(ODE-183) May 04, 2025
Orphan Drug Exclusivity(ODE-148) Jun 22, 2024
New Indication(I-908) Mar 16, 2026
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030
New Indication(I-895) Jun 22, 2025
Pediatric Exclusivity(PED) Dec 22, 2025
New Indication(I-745) Jun 22, 2020
Orphan Drug Exclusivity(ODE-48) May 29, 2020
M(M-170) Nov 20, 2018
Orphan Drug Exclusivity(ODE-57) Jan 08, 2021
New Indication(I-678) Jan 08, 2017
M(M-246) Oct 06, 2022
New Indication(I-778) Apr 30, 2021
New Indication(I-781) May 04, 2021
Orphan Drug Exclusivity(ODE) May 29, 2020
New Chemical Entity Exclusivity(NCE) May 29, 2018

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Treatment: In combination with dabrafenib for the treatment of unresectable or metastatic melanoma.; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small...

Dosage: TABLET;ORAL

More Information on Dosage

MEKINIST family patents

Family Patents

20. Myfembree patents expiration

MYFEMBREE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2025

(7 months from now)

US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2025

(7 months from now)

US11795178 MYOVANT SCIENCES Compositions of thienopyrimidine derivatives
Sep, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9346822 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Feb, 2024

(3 months ago)

US11033551 MYOVANT SCIENCES Methods of treating uterine fibroids
Sep, 2037

(13 years from now)

US11793812 MYOVANT SCIENCES Methods of treating endometriosis
May, 2038

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2025
New Product(NP) May 26, 2024
M(M-289) Jan 27, 2026
New Indication(I-898) Aug 05, 2025

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 26 May, 2021

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women; Management of moderate to severe pain associated with endometriosis

Dosage: TABLET;ORAL

More Information on Dosage

MYFEMBREE family patents

Family Patents

21. Nexletol patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7335799 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2025

(1 year, 5 months from now)

US11613511 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(16 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497301 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(5 months ago)

US10941095 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(5 months ago)

US9000041 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(5 months ago)

US9624152 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(5 months ago)

US10118881 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(5 months ago)

US11926584 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(16 years from now)

US11760714 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 21, 2025

Drugs and Companies using BEMPEDOIC ACID ingredient

NCE-1 date: 22 February, 2024

Market Authorisation Date: 21 February, 2020

Treatment: Use of nexletol as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular dise...

Dosage: TABLET;ORAL

More Information on Dosage

NEXLETOL family patents

Family Patents

22. Nexlizet patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7335799 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2025

(1 year, 5 months from now)

US11613511 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(16 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10941095 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(5 months ago)

US10118881 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(5 months ago)

US9624152 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(5 months ago)

US9000041 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(5 months ago)

US8497301 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2023

(5 months ago)

US10912751 ESPERION THERAPS INC Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Mar, 2036

(11 years from now)

US11744816 ESPERION THERAPS INC Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Mar, 2036

(11 years from now)

US11926584 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(16 years from now)

US11760714 ESPERION THERAPS INC Methods of making bempedoic acid and compositions of the same
Jun, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 21, 2025
New Product(NP) Feb 26, 2023

Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient

NCE-1 date: 22 February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular dise...

Dosage: TABLET;ORAL

More Information on Dosage

NEXLIZET family patents

Family Patents

23. Nurtec Odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8314117 PFIZER CGRP receptor antagonists
Mar, 2030

(5 years from now)

US8759372 PFIZER N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt
Feb, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11083724 PFIZER Rimegepant for CGRP related disorders
Mar, 2039

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 27, 2025
New Indication(I-865) May 27, 2024

Drugs and Companies using RIMEGEPANT SULFATE ingredient

NCE-1 date: 28 February, 2024

Market Authorisation Date: 27 February, 2020

Treatment: Preventive treatment of episodic migraine in adults

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

NURTEC ODT family patents

Family Patents

24. Olinvyk patents expiration

OLINVYK's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11931350 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)

US11077098 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)

US9309234 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)

US8835488 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9642842 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 30, 2025

Drugs and Companies using OLICERIDINE ingredient

NCE-1 date: 30 October, 2024

Market Authorisation Date: 30 October, 2020

Treatment: Management of acute pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

OLINVYK family patents

Family Patents

25. Ongentys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8907099 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
May, 2027

(2 years from now)

US8168793 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
Apr, 2029

(4 years from now)

US9630955 NEUROCRINE Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor
Dec, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550759 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
Jul, 2026

(2 years from now)

US9745290 NEUROCRINE Dosage regimen for COMT inhibitors
Oct, 2027

(3 years from now)

US8524746 NEUROCRINE Dosage regimen for COMT inhibitors
Jul, 2029

(5 years from now)

US10583130 NEUROCRINE Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof
Mar, 2030

(5 years from now)

US10071085 NEUROCRINE Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
Mar, 2030

(5 years from now)

US10357468 NEUROCRINE Medicaments for slowing Parkinson's disease
May, 2035

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: 24 April, 2024

Market Authorisation Date: 24 April, 2020

Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson’s disease experiencing off episodes by reducing o-methylation of l-dopa; Adjunctive treatment to levodopa/carbidopa in patients wi...

Dosage: CAPSULE;ORAL

More Information on Dosage

ONGENTYS family patents

Family Patents

26. Orgovyx patents expiration

ORGOVYX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8058280 SUMITOMO PHARMA Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2025

(7 months from now)

US7300935 SUMITOMO PHARMA Thienopyrimidine compounds and use thereof
Jan, 2025

(7 months from now)

US11795178 SUMITOMO PHARMA Compositions of thienopyrimidine derivatives
Sep, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735401 SUMITOMO PHARMA Thienopyrimidine compounds and use thereof
Feb, 2024

(4 months ago)

US10350170 SUMITOMO PHARMA Solid preparation
Feb, 2036

(11 years from now)

US10786501 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(13 years from now)

US11583526 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(13 years from now)

US10449191 SUMITOMO PHARMA Treatment of prostate cancer
Sep, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

ORGOVYX family patents

Family Patents

27. Orladeyo patents expiration

Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10329260 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(10 years from now)

US10125102 BIOCRYST Human plasma kallikrein inhibitors
Apr, 2035

(10 years from now)

US10662160 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10689346 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(10 years from now)

US11708333 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(10 years from now)

US11230530 BIOCRYST Human plasma kallikrein inhibitors
Mar, 2035

(10 years from now)

US11618733 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(15 years from now)

US11117867 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-333) Dec 03, 2027
New Chemical Entity Exclusivity(NCE) Dec 03, 2025

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

NCE-1 date: 03 December, 2024

Market Authorisation Date: 03 December, 2020

Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older

Dosage: CAPSULE;ORAL

More Information on Dosage

ORLADEYO family patents

Family Patents

28. Oxlumo patents expiration

Can you believe OXLUMO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(4 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(5 years from now)

US11060093 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

US9828606 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

US10487330 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

US10465195 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(11 years from now)

US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(11 years from now)

US10612027 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(11 years from now)

US10478500 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
Oct, 2035

(11 years from now)

US11446380 ALNYLAM PHARMS INC Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Oct, 2035

(11 years from now)

US11261447 ALNYLAM PHARMS INC Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Nov, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435692 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-339) Nov 23, 2027
New Chemical Entity Exclusivity(NCE) Nov 23, 2025
Orphan Drug Exclusivity(ODE-415) Oct 06, 2029
New Indication(I-901) Oct 06, 2025

Drugs and Companies using LUMASIRAN SODIUM ingredient

NCE-1 date: 23 November, 2024

Market Authorisation Date: 23 November, 2020

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

OXLUMO family patents

Family Patents

29. Pemazyre patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9611267 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jan, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10131667 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jun, 2033

(9 years from now)

US11466004 INCYTE CORP Solid forms of an FGFR inhibitor and processes for preparing the same
May, 2039

(14 years from now)

US11628162 INCYTE CORP Methods of treating cancer with an FGFR inhibitor
Aug, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 17, 2025
Orphan Drug Exclusivity(ODE-292) Apr 17, 2027
Orphan Drug Exclusivity(ODE-404) Aug 26, 2029
New Indication(I-899) Aug 26, 2025

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: 17 April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement; Treatment of p...

Dosage: TABLET;ORAL

More Information on Dosage

PEMAZYRE family patents

Family Patents

30. Pizensy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10806743 BRAINTREE LABS Method of administering lactitol to reduce plasma concentration of lactitol
May, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 12, 2025

Drugs and Companies using LACTITOL ingredient

NCE-1 date: 13 February, 2024

Market Authorisation Date: 12 February, 2020

Treatment: Method of treating chronic idiopathic constipation in adult patients.

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

PIZENSY family patents

Family Patents

31. Qinlock patents expiration

Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8188113 DECIPHERA PHARMS Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jul, 2030

(6 years from now)

US8461179 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
May, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940756 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jun, 2032

(8 years from now)

USRE48731 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jun, 2032

(8 years from now)

US10966966 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11426390 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11433056 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11576904 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11529336 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11534432 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11266635 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11344536 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11813251 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(16 years from now)

US11903933 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11844788 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11850240 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11612591 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11185535 DECIPHERA PHARMS Amorphous kinase inhibitor formulations and methods of use thereof
Dec, 2040

(16 years from now)

US11911370 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11896585 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11395818 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11801237 DECIPHERA PHARMS Amorphous kinase inhibitor formulations and methods of use thereof
Dec, 2040

(16 years from now)

US11850241 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11793795 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11918564 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11576903 DECIPHERA PHARMS Amorphous kinase inhibitor formulations and methods of use thereof
Dec, 2040

(16 years from now)

US11779572 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Oct, 2042

(18 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 15, 2025
Orphan Drug Exclusivity(ODE-298) May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: 15 May, 2024

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of gastrointestinal stromal tumors; Treatment of gastrointestinal stromal tumor; Treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administ...

Dosage: TABLET;ORAL

More Information on Dosage

QINLOCK family patents

Family Patents

32. Retevmo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10112942 LOXO ONCOL ELI LILLY Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(13 years from now)

US10584124 LOXO ONCOL ELI LILLY Crystalline forms
Oct, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10137124 LOXO ONCOL ELI LILLY Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Oct, 2037

(13 years from now)

US10172851 LOXO ONCOL ELI LILLY Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(13 years from now)

US10786489 LOXO ONCOL ELI LILLY Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile
Oct, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 08, 2025
Orphan Drug Exclusivity(ODE-301) May 08, 2027
Orphan Drug Exclusivity(ODE-303) May 08, 2027
Orphan Drug Exclusivity(ODE-302) May 08, 2027
Orphan Drug Exclusivity(ODE-409) Sep 21, 2029
Orphan Drug Exclusivity(ODE-412) Sep 21, 2029

Drugs and Companies using SELPERCATINIB ingredient

NCE-1 date: 08 May, 2024

Market Authorisation Date: 08 May, 2020

Treatment: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (mtc) with a ret mutation, as detected by an fda-approved test, who require sys...

Dosage: CAPSULE;ORAL

More Information on Dosage

RETEVMO family patents

Family Patents

33. Reyvow patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7423050 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Feb, 2028

(3 years from now)

US11053214 ELI LILLY AND CO Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Dec, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748459 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Mar, 2023

(1 year, 2 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2025

Drugs and Companies using LASMIDITAN SUCCINATE ingredient

NCE-1 date: 01 February, 2024

Market Authorisation Date: 31 January, 2020

Treatment: Acute treatment of migraine

Dosage: TABLET;ORAL

More Information on Dosage

REYVOW family patents

Family Patents

34. Rukobia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8461333 VIIV HLTHCARE Salts of prodrugs of piperazine and substituted piperidine antiviral agents
Feb, 2025

(8 months from now)

US7745625 VIIV HLTHCARE Prodrugs of piperazine and substituted piperidine antiviral agents
Nov, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168615 VIIV HLTHCARE Prodrugs of piperazine and substituted piperidine antiviral agents
Jul, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 02, 2025

Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient

NCE-1 date: 02 July, 2024

Market Authorisation Date: 02 July, 2020

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

RUKOBIA family patents

Family Patents

35. Tabrecta patents expiration

TABRECTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8461330 NOVARTIS PHARM Imidazotriazines and imidazopyrimidines as kinase inhibitors
Nov, 2027

(3 years from now)

US7767675 NOVARTIS PHARM Imidazotriazines and imidazopyrimidines as kinase inhibitors
Nov, 2027

(3 years from now)

US8420645 NOVARTIS PHARM Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
Jun, 2031

(6 years from now)

US10596178 NOVARTIS PHARM Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
Jul, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8901123 NOVARTIS PHARM Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
May, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 06, 2025
Orphan Drug Exclusivity(ODE-291) May 06, 2027

Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient

NCE-1 date: 06 May, 2024

Market Authorisation Date: 06 May, 2020

Treatment: Use for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with a mesenchymal-epithelial transition (met) exon 14 skipping mutation

Dosage: TABLET;ORAL

More Information on Dosage

TABRECTA family patents

Family Patents

36. Tafinlar patents expiration

TAFINLAR's oppositions filed in EPO
Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8415345 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jan, 2030

(5 years from now)

US7994185 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jan, 2030

(5 years from now)

US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(1 year, 1 day from now)

US8835443

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Dec, 2025

(1 year, 6 months from now)

US9233956 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
May, 2029

(4 years from now)

US9233956

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Nov, 2029

(5 years from now)

US7994185

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jul, 2030

(6 years from now)

US8415345

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jul, 2030

(6 years from now)

US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Oct, 2030

(6 years from now)

US8703781

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Apr, 2031

(6 years from now)

US8952018

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Apr, 2031

(6 years from now)

US10869869 NOVARTIS Method of adjuvant cancer treatment
Aug, 2033

(9 years from now)

US10869869

(Pediatric)

NOVARTIS Method of adjuvant cancer treatment
Mar, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-182) Apr 30, 2025
Orphan Drug Exclusivity(ODE-183) May 04, 2025
Orphan Drug Exclusivity(ODE-147) Jun 22, 2024
Orphan Drug Exclusivity(ODE-428) Mar 16, 2030
New Indication(I-908) Mar 16, 2026
New Indication(I-894) Jun 22, 2025
Pediatric Exclusivity(PED) Dec 22, 2025
New Indication(I-745) Jun 22, 2020
New Indication(I-678) Jan 08, 2017
M(M-170) Nov 20, 2018
M(M-246) Oct 06, 2022
Orphan Drug Exclusivity(ODE-47) May 29, 2020
Orphan Drug Exclusivity(ODE-58) Jan 09, 2021
New Indication(I-778) Apr 30, 2021
New Indication(I-781) May 04, 2021
Orphan Drug Exclusivity(ODE) May 29, 2020
New Chemical Entity Exclusivity(NCE) May 29, 2018

Drugs and Companies using DABRAFENIB MESYLATE ingredient

NCE-1 date: 22 December, 2024

Market Authorisation Date: 29 May, 2013

Treatment: Tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of ...

Dosage: CAPSULE;ORAL

More Information on Dosage

TAFINLAR family patents

Family Patents

37. Tauvid patents expiration

TAUVID's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8932557 AVID RADIOPHARMS INC Imaging agents for detecting neurological dysfunction
May, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2025

Drugs and Companies using FLORTAUCIPIR F-18 ingredient

NCE-1 date: 28 May, 2024

Market Authorisation Date: 28 May, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

TAUVID family patents

Family Patents

38. Tazverik patents expiration

TAZVERIK's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9090562 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Sep, 2031

(7 years from now)

US11052093 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Apr, 2032

(7 years from now)

US10821113 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(8 years from now)

US9394283 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(8 years from now)

US8410088 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Jan, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8691507 EPIZYME INC Inhibitors of human EZH2 and methods of use thereof
Sep, 2031

(7 years from now)

US9175331 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof
Sep, 2031

(7 years from now)

US8895245 EPIZYME INC Inhibitors of human EZH2 and methods of use thereof
Sep, 2031

(7 years from now)

US9949999 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof
Sep, 2031

(7 years from now)

US10420775 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Sep, 2031

(7 years from now)

US9333217 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof
Sep, 2031

(7 years from now)

US10155002 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Sep, 2031

(7 years from now)

US9549931 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Sep, 2031

(7 years from now)

US8765732 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Sep, 2031

(7 years from now)

US9334527 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof
Sep, 2031

(7 years from now)

US9855275 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Sep, 2031

(7 years from now)

US9522152 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(7 years from now)

US10245269 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(8 years from now)

US11491163 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(8 years from now)

US9872862 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(8 years from now)

US9688665 EPIZYME INC Methods of treating cancer
Aug, 2034

(10 years from now)

US9889138 EPIZYME INC Method for treating cancer
Oct, 2035

(11 years from now)

US10369155 EPIZYME INC Method for treating cancer
Oct, 2035

(11 years from now)

US10786511 EPIZYME INC Method for treating cancer
Dec, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 23, 2025
Orphan Drug Exclusivity(ODE-314) Jun 18, 2027
Orphan Drug Exclusivity(ODE-299) Jan 23, 2027
New Indication(I-835) Jun 18, 2023
New Indication(I-836) Jun 18, 2023

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

NCE-1 date: 24 January, 2024

Market Authorisation Date: 23 January, 2020

Treatment: Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating relapsed or refractory follicular lymphoma positive for an...

Dosage: TABLET;ORAL

More Information on Dosage

TAZVERIK family patents

Family Patents

39. Tukysa patents expiration

TUKYSA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7452895 SEAGEN Quinazoline analogs as receptor tyrosine kinase inhibitors
Nov, 2024

(5 months from now)

US8648087 SEAGEN N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
Apr, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9693989 SEAGEN N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
May, 2027

(2 years from now)

US9457093 SEAGEN Solid dispersions of a ERB2 (HER2) inhibitor
Oct, 2032

(8 years from now)

US11504370 SEAGEN Treatment of brain cancer
Mar, 2033

(8 years from now)

US11207324 SEAGEN Treatment of HER2 positive cancers
Apr, 2038

(13 years from now)

US11666572 SEAGEN Treatment of HER2 positive cancers
Apr, 2038

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-309) Apr 17, 2027
New Chemical Entity Exclusivity(NCE) Apr 17, 2025
New Indication(I-906) Jan 19, 2026
Orphan Drug Exclusivity(ODE-422) Jan 19, 2030

Drugs and Companies using TUCATINIB ingredient

NCE-1 date: 17 April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer; Combination treatment with tucatinib and trastuzumab of adults with ras wild-type her2-positive unresectabl...

Dosage: TABLET;ORAL

More Information on Dosage

TUKYSA family patents

Family Patents

40. Viltepso patents expiration

VILTEPSO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9079934 NIPPON SHINYAKU Antisense nucleic acids
Aug, 2031

(7 years from now)

US10870676 NIPPON SHINYAKU Antisense nucleic acids
Aug, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 12, 2025
Orphan Drug Exclusivity(ODE-280) Aug 12, 2027

Drugs and Companies using VILTOLARSEN ingredient

NCE-1 date: 12 August, 2024

Market Authorisation Date: 12 August, 2020

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

VILTEPSO family patents

Family Patents

41. Winlevi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8865690 SUN PHARM 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents
Jul, 2024

(a month from now)

US9211295 SUN PHARM 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents
Jul, 2024

(a month from now)

US8143240 SUN PHARM 17α, 21-dihydroxypregnene esters as antiandrogenic agents
Jan, 2025

(7 months from now)

US9486458 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Jul, 2028

(4 years from now)

US10159682 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Aug, 2028

(4 years from now)

US11207332 SUN PHARM Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Nov, 2028

(4 years from now)

US9433628 SUN PHARM Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Feb, 2029

(4 years from now)

US8785427 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 26, 2025

Drugs and Companies using CLASCOTERONE ingredient

NCE-1 date: 26 August, 2024

Market Authorisation Date: 26 August, 2020

Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate; Method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate

Dosage: CREAM;TOPICAL

More Information on Dosage

WINLEVI family patents

Family Patents

42. Xarelto patents expiration

XARELTO's oppositions filed in EPO
XARELTO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7585860 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Dec, 2020

(3 years ago)

US7157456 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Aug, 2024

(2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7592339 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Dec, 2020

(3 years ago)

US7585860 JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Dec, 2020

(3 years ago)

US9415053 JANSSEN PHARMS Solid, orally administrable pharmaceutical composition
Nov, 2024

(5 months from now)

US7157456

(Pediatric)

JANSSEN PHARMS Substituted oxazolidinones and their use in the field of blood coagulation
Feb, 2025

(8 months from now)

US9415053

(Pediatric)

JANSSEN PHARMS Solid, orally administrable pharmaceutical composition
May, 2025

(11 months from now)

US9539218 JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Feb, 2034

(9 years from now)

US9539218

(Pediatric)

JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Aug, 2034

(10 years from now)

US10828310 JANSSEN PHARMS Reducing the risk of cardiovascular events
Jan, 2039

(14 years from now)

US10828310

(Pediatric)

JANSSEN PHARMS Reducing the risk of cardiovascular events
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-867) Aug 23, 2024
Pediatric Exclusivity(PED) Feb 23, 2025
New Indication(I-824) Oct 11, 2021
New Dosing Schedule(D-168) Oct 27, 2020
New Indication(I-810) Oct 11, 2022
M(M-284) Mar 10, 2023
New Indication(I-660) Nov 02, 2015
New Indication(I-661) Nov 02, 2015
New Indication(I-662) Nov 02, 2015
New Chemical Entity Exclusivity(NCE) Jul 01, 2016
New Indication(I-643) Nov 04, 2014

Drugs and Companies using RIVAROXABAN ingredient

NCE-1 date: 24 February, 2024

Market Authorisation Date: 11 October, 2018

Treatment: Prophylaxis of deep vein thrombosis (dvt); Reduction in the risk of recurrence of deep vein thrombosis (dvt) and pulmonary embolism; Treatment of venous thromboembolism (vte) and the reduction in the ...

Dosage: TABLET;ORAL

How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage

XARELTO family patents

Family Patents

43. Xcopri patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598279 SK LIFE Neurotherapeutic azole compounds
Oct, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11654133 SK LIFE Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 10, 2025

Drugs and Companies using CENOBAMATE ingredient

NCE-1 date: 10 March, 2024

Market Authorisation Date: 10 March, 2020

Treatment: Co-administration of cenobamate with phenobarbital and/or phenytoin for the treatment of partial onset seizures

Dosage: TABLET;ORAL

More Information on Dosage

XCOPRI family patents

Family Patents

44. Xeglyze patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9839631 HATCHTECH Methods and compositions for controlling ectoparasites
Jul, 2024

(a month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9357783 HATCHTECH Methods and compositions for controlling ectoparasites
Jul, 2024

(a month from now)

US8212038 HATCHTECH Methods and compositions for controlling ectoparasites
Jul, 2024

(a month from now)

US7812163 HATCHTECH Methods and compositions for controlling ectoparasites
Oct, 2026

(2 years from now)

US10292389 HATCHTECH Pediculicidal composition
Dec, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 24, 2025

Drugs and Companies using ABAMETAPIR ingredient

NCE-1 date: 24 July, 2024

Market Authorisation Date: 24 July, 2020

Treatment: Topical treatment of head lice infestation in patients 6 months of age and older

Dosage: LOTION;TOPICAL

More Information on Dosage

XEGLYZE family patents

Family Patents

45. Zeposia patents expiration

ZEPOSIA's oppositions filed in EPO
Can you believe ZEPOSIA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8481573 BRISTOL Modulators of sphingosine phosphate receptors
May, 2029

(4 years from now)

US8796318 BRISTOL Modulators of sphingosine phosphate receptors
May, 2029

(4 years from now)

US11680050 BRISTOL Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
Sep, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9382217 BRISTOL Modulators of sphingosine phosphate receptors
May, 2029

(4 years from now)

US10239846 BRISTOL Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
Nov, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 25, 2025
New Indication(I-860) May 27, 2024

Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient

NCE-1 date: 25 March, 2024

Market Authorisation Date: 25 March, 2020

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Treatment of moderat...

Dosage: CAPSULE;ORAL

More Information on Dosage

ZEPOSIA family patents

Family Patents

46. Zepzelca patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7763615 JAZZ Ecteinascidin analogs for use as antitumour agents
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 15, 2025
Orphan Drug Exclusivity(ODE-304) Jun 15, 2027

Drugs and Companies using LURBINECTEDIN ingredient

NCE-1 date: 15 June, 2024

Market Authorisation Date: 15 June, 2020

Treatment: Treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy.

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ZEPZELCA family patents

Family Patents

47. Zokinvy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7838531 EIGER BIOPHARMS Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Jul, 2024

(a month from now)

US8828356 EIGER BIOPHARMS Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Oct, 2024

(4 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-324) Nov 20, 2027
New Chemical Entity Exclusivity(NCE) Nov 20, 2025

Drugs and Companies using LONAFARNIB ingredient

NCE-1 date: 20 November, 2024

Market Authorisation Date: 20 November, 2020

Treatment: Reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps)

Dosage: CAPSULE;ORAL

More Information on Dosage

ZOKINVY family patents

Family Patents